Cousins Properties' (CUZ) Heights Union Buyout Fails to Drive Stock
The acquisition of Heights Union is in line with Cousins Properties' (CUZ) efforts to enhance its portfolio quality with trophy assets.
Shares of Cousins Properties CUZ have seen no significant movement since it announced the acquisition of Heights Union in the Heights neighborhood of Downtown Tampa for $144.8 million earlier this week. The buyout comes as part of company’s efforts to upgrade its portfolio quality with trophy assets.
The 294,000-square-foot office property completed in late 2020 is now 93.4% leased. With an advantageous location, the property has an attractive customer base.
The Heights is a live-work-play district and attracts a huge crowd. Anchored by Armature Works, the district holds more than 20 restaurants and bars. This reflects that the location is apt for Cousins Properties to grow via acquisitions.
Heights Union enjoys an outstanding rent roll, with the life-science customers representing 66% of the rent roll. Pfizer PFE has a leased 106,000 square feet of the property for a Global Capability Hub, while AxoGen AXGN has leased 75,000 square feet for its second headquarters and lab space.
The buyout of this property seems a strategic fit for Cousins Properties as the demand for office spaces has been high amid the favorable migration trends and pro-business environment.
Cousins Properties has an unmatched portfolio of class A office assets concentrated in the high-growth Sun Belt markets. In July, the company had acquired 725 Ponce, a 372,000-square-foot office asset for $300.2 million in Midtown Atlanta. The REIT is also well placed to cater to the demand for highly-amenitized office assets. However, stiff competition will likely dent occupancy growth.
Cousins Properties currently carries a Zacks Rank #3 (Hold). The company’s shares have gained 4% compared with the industry’s decline of 3.2% over the past three months.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for OUTFRONT Media’s OUT ongoing-year FFO per share has moved 8% north over the past two months. The company sports a Zacks Rank of 1 (Strong Buy), currently. You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Cousins Properties Incorporated (CUZ): Free Stock Analysis Report
AxoGen, Inc. (AXGN): Free Stock Analysis Report
OUTFRONT Media Inc. (OUT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research